Celltrion wins 3 biosimilar approvals in Australia, eyes Oceania growth
According to the biosimilar maker, the approvals from Australia's Therapeutic Goods Administration cover eye treatment Eydenzelt, its version of Regeneron Pharmaceuticals' Eylea, as well as two bone-related therapies Stoboclo and Osenvelt, referencing Amgen's Prolia and Xgeva, respectively.
With the newest additions, Celltrion now has 11 products either approved or marketed in Australia.
'Australia's biosimilar-friendly environment continues to spur our growth momentum,' a company official said. 'We aim to complete the remaining commercialization steps swiftly to ensure stable supply in the market.'
Eydenzelt, available in both vial and prefilled syringe forms, has been approved for the treatment of myopic choroidal neovascularization, or CNV, making it the first biosimilar in its category to gain approval in Australia.
Its reference product, Eylea, generated $9.52 billion in global sales last year, underlining strong market potential, the company noted.
Stoboclo and Osenvelt were approved for all indications held by their reference biologics in Australia.
Stoboclo is indicated for postmenopausal osteoporosis, while Osenvelt is approved for preventing skeletal-related events in cancer patients with bone metastases and for treating giant cell tumors of bone. Their originator drugs Prolia and Xgeva recorded a combined $6.59 billion in global sales last year.
The company said the approvals mark a key milestone in expanding its global reach, including in the Oceania region, with additional plans to broaden its pipeline in ophthalmology and bone-related therapies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
5 days ago
- Korea Herald
Celltrion's Q2 net falls 19.3% on provisions
Celltrion, a major South Korean biopharmaceutical company, said Wednesday its second-quarter net profit fell 19.3 percent from a year earlier due to provisions related to ongoing legal disputes. For the three months ended June 30, net profit declined to 63.3 billion won ($45.6 million) from 78.4 billion won in the same period last year, the company said in a regulatory filing. "We set aside provisions in preparation for potential compensation related to ongoing legal disputes. These provisions impacted our quarterly bottom line," a company spokesperson said, without elaborating. Operating profit more than tripled to 242.5 billion won from 72.4 billion won, while sales rose 9.9 percent to 961.5 billion won from 874.7 billion won. The company said increased global sales of its flagship biosimilars, including Remsima SC, Yuflyma and Vegzelma, supported quarterly earnings. These high-margin products accounted for 53 percent of total sales in the second quarter. In the first half of the year, net income surged 73 percent to 171.6 billion won from 99.2 billion won a year earlier. Celltrion expects strong earnings to continue in the second half, as it plans to gradually launch five new biosimilars -- Omlyclo, Avtozma, Eydenzelt, Stoboclo and Osenvelt -- in global markets later this year. The company aims to achieve 5 trillion won in annual sales this year, up 40 percent from a record 3.56 trillion won last year. Celltrion has significantly expanded its global biosimilar portfolio, with the number of approved products rising from six to 11. It plans to commercialize 22 biosimilar products by 2030, when the global market is projected to grow to 261 trillion won from 138 trillion won this year. (Yonhap)
Korea Herald
29-07-2025
- Korea Herald
Celltrion nears US plant deal to go ‘made in USA'
Biosimilar giant to invest W700b in new US plant, double spending for expansion, chief says Celltrion Group Chairman and founder Seo Jung-jin said Tuesday that the company is preparing for new US tariffs by moving closer to acquiring a biologics manufacturing facility in the United States -- a move that would give Celltrion greater access to a market Seo framed as 'indispensable.' According to a regulatory filing Tuesday, Celltrion has been named the preferred bidder for a large-scale biologics manufacturing facility in the US, a cGMP or "current Good Manufacturing Practice" drug substance site located within a major pharmaceutical hub. The seller and deal value remain under wraps pending final agreement, expected in early October. 'The US is simply too big a market to walk away from, and we're aiming to eliminate uncertainty in our US sales,' said Seo during a livestreamed press conference Tuesday. 'If the US government wants drugs to be made in the US, then our plan is to produce them there accordingly.' Celltrion currently sells 11 biosimilars in the US, with plans to expand its portfolio to 22 by 2030 and 41 by 2033. It is also conducting Phase 1 trials for four novel drug candidates this year, with the goal of submitting investigational new drug applications for a total of 13 by 2028. Once due diligence is complete and the acquisition finalized, Celltrion is set to largely eliminate tariff-related risks for its pharmaceutical products in the US, backed by two years' worth of US-bound inventory and expanded contracts with local contract manufacturers. The deal includes a contract manufacturing agreement covering 50 percent of the facility's capacity, granting exclusive rights to produce the seller's biologics for five years. 'That means we won't be operating at a loss from day one,' Seo continued. 'The other half will be used to manufacture our own products for the US market.' He added that the potential acquisition brings a team of development personnel, which would complement Celltrion's existing research capabilities. Celltrion is also considering follow-up investments depending on how US tariff policies take shape. While the total cost of acquiring and operating the facility is expected to reach roughly 700 billion won ($503 million), Seo said a minor expansion could require an additional 300 billion won. 'In the case of a large-scale buildout, we estimate up to 700 billion won in extra investment,' he said. The expanded facility would be up to 1.5 times the size of Celltrion's second plant in Songdo, Incheon, he added. While highlighting the cost and time advantages of acquiring an existing facility, Seo noted that competition would likely remain limited due to high capital requirements and long lead times for local production. 'We believe US drug prices are likely to rise, and for companies that complete local production early, this could be a major opportunity,' he noted. As for the sales outlook, Seo said the company is on track to deliver 4.5 to 4.6 trillion won in sales this year -- of Celltrion's five trillion won full-year goal -- with operating profit expected to reach about 1.5 trillion won. In the second quarter, Celltrion posted record revenue and operating profit, with revenue rising 9.9 percent from a year earlier to 961.5 billion won and operating profit jumping 234.5 percent to 242.5 billion won.
Korea Herald
28-07-2025
- Korea Herald
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
DAEJEON, South Korea, July 28, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI ® (code name: ALT-L9), a biosimilar referencing Eylea ® (aflibercept), co-developed with its subsidiary Alteogen Biologics Inc. EYLUXVI ® has been recommended for approval in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch [RVO] or central [RVO]), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV). "We are pleased to receive a positive CHMP recommendation for EYLUXVI ®. This marks a significant milestone for Alteogen," said Soon-Jae Park, PhD, Chief Executive Officer of Alteogen. "We will provide a new, accessible treatment option for patients suffering from devastating ocular diseases such as wet age-related macular degeneration," he added. The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI ® and reference aflibercept in patients with wet AMD. Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin ® biosimilar, ALT-L2, for the Chinese market to Qilu Pharmaceutical in 2017. Qilu Pharmaceutical completed its development, obtained approval from Chinese regulatory authorities last year, and is currently marketing the product in China. If approved, EYLUXVI ® will be Alteogen's second commercialized biosimilar product. About the ALT-L9 Phase 3 study The study is a randomized, double-masked, parallel group phase 3 study conducted at 79 centers in 12 countries from June 2022 to February 2024, including follow-up through 52 weeks. 431 participants with wet AMD were randomized 1:1 to receive either ALT-L9 (n = 216) or Eylea® (n = 215). The primary efficacy endpoint of the study was the change from baseline in best corrected visual acuity (BCVA). About Alteogen Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ ( For more information, please visit: Contacts:
